We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+14.95%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.78B
AUM Growth
-$802M
Cap. Flow
-$1.61B
Cap. Flow %
-18.35%
Top 10 Hldgs %
33.27%
Holding
157
New
20
Increased
27
Reduced
40
Closed
17

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$131M
2
MRK icon
Merck
MRK
+$97.5M
3
EW icon
Edwards Lifesciences
EW
+$97.4M
4
AGN.PRA
Allergan plc
AGN.PRA
+$76.2M
5
BOLD
Audentes Therapeutics, Inc
BOLD
+$72.9M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$213M
2
BMY icon
Bristol-Myers Squibb
BMY
+$184M
3
ABBV icon
AbbVie
ABBV
+$152M
4
BSX icon
Boston Scientific
BSX
+$141M
5
AGN
Allergan plc
AGN
+$138M

Sector Composition

Rank Sector Weight
1 Healthcare 92.67%
2 Financials 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
76
Xencor
XNCR
$1.48B
$18.2M 0.21%
744,522
-126,300
-15% -$2.67M
CHRS icon
77
Coherus Oncology
CHRS
$219M
$18M 0.2%
+671,600
New +$18.3M
RCKT icon
78
Rocket Pharmaceuticals
RCKT
$341M
$17.5M 0.2%
462,325
+114,575
+33% +$3.6M
FWP
79
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$16.8M 0.19%
114,000
– –
IMGN
80
DELISTED
Immunogen Inc
IMGN
$16.3M 0.19%
6,095,647
– –
SRPT icon
81
Sarepta Therapeutics
SRPT
$1.66B
$16.1M 0.18%
+261,800
New +$7.91M
ARWR icon
82
Arrowhead Research
ARWR
$12.1B
$15.9M 0.18%
+2,159,973
New +$14M
SVA
83
DELISTED
Sinovac Biotech, Ltd
SVA
$15.7M 0.18%
2,667,500
– –
PRQR icon
84
ProQR Therapeutics
PRQR
$250M
$15.4M 0.18%
2,305,446
– –
DERM
85
DELISTED
Dermira, Inc.
DERM
$14.4M 0.16%
+425,600
New +$13.7M
NTRA icon
86
Natera
NTRA
$36.5B
$14.2M 0.16%
1,276,190
– –
LAB icon
87
Standard BioTools
LAB
$344M
$14M 0.16%
1,746,100
– –
AET
88
DELISTED
Aetna Inc
AET
$13.5M 0.15%
116,600
– –
PVLA
89
Palvella Therapeutics
PVLA
$2.07B
$13.3M 0.15%
90,745
– –
BCR
90
DELISTED
CR Bard Inc.
BCR
$13M 0.15%
58,000
+35,000
+152% +$7.88M
DBVT
91
DBV Technologies
DBVT
$797M
$12.6M 0.14%
+34,570
New +$12M
VNDA icon
92
CALL
Vanda Pharmaceuticals
VNDA
$298M
$12.5M 0.14%
+750,000
New +$10.1M
IMMU
93
DELISTED
Immunomedics Inc
IMMU
$12.4M 0.14%
3,802,000
– –
RARE icon
94
Ultragenyx Pharmaceutical
RARE
$2.5B
$12M 0.14%
169,300
– –
AGN
95
CALL
DELISTED
Allergan plc
AGN
$11.5M 0.13%
50,000
-100,000
-67% -$24.4M
SNDX icon
96
Syndax Pharmaceuticals
SNDX
$1.73B
$11.5M 0.13%
757,365
– –
STDY
97
DELISTED
SteadyMed Ltd
STDY
$11M 0.13%
+3,072,196
New +$10.5M
SAGE
98
DELISTED
Sage Therapeutics
SAGE
$10.8M 0.12%
+235,400
New +$9.58M
ASMB icon
99
Assembly Biosciences
ASMB
$493M
$10.1M 0.11%
116,425
– –
AFMD
100
DELISTED
Affimed
AFMD
$9.38M 0.11%
337,500
-40,000
-11% -$1.12M
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2016 Portfolio in Review

As of Q3 2016, OrbiMed held 157 positions worth $8.78B, down 8.4% from $9.58B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed withdrew a net $1.61B in Q3 2016, closing 17 positions and reducing 40 holdings. Its most notable exit was RELYPSA INC COM, an estimated $137M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Allergan plc worth $72.5M.

  • OrbiMed's largest Q3 2016 buy was Allergan plc: 88,200 shares worth $72.5M.
  • OrbiMed added most to Shire pic in Q3 2016, an estimated $131M increase.
  • OrbiMed's biggest Q3 2016 reduction was HCA Healthcare, cutting an estimated $213M.
  • OrbiMed fully exited RELYPSA INC COM in Q3 2016, selling an estimated $137M.
  • OrbiMed's ten largest holdings make up 33% of its $8.78B portfolio in Q3 2016.
  • OrbiMed opened 20 new positions and closed 17 in Q3 2016.
  • OrbiMed's portfolio value fell 8.4% quarter-over-quarter to $8.78B.

Based on OrbiMed's 13F filing for Q3 2016, filed 14 Nov 2016.